Edwards Lifesciences Corp (NYSE: EW). Extremely important negative changes in investment behavior have recently occurred: the stock’s recent price decline challenged its longer term uptrend, its shorter term price trend turned down, the stock fell on very heavy volume, and its longer term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
EW’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Edwards Lifesciences has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Edwards Lifesciences has a poor Appreciation Score of 28 but a good Power Rating of 77, resulting in the Neutral Value Trend Rating.
Recent Price Action
Edwards Lifesciences Corp (NYSE: EW) stock closed at $63.64 on 7/30/24 after a slight decline of -0.2%. Moreover, trading volume in this decline was exceptionally high at 207% of normal. The stock has declined -27.7% during the last week but has been strong relative to the market over the last nine months.
Be the first to comment